Abciximab readministration

Reviews in Cardiovascular Medicine

Volumn 3, Issue 2, 2002, Pages 67-70

  Orford, James L ^a   Holmes Jr , David R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Abciximab; IIb IIIa receptor inhibitors; Percutaneous coronary intervention; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ALLERGIC REACTION; ANAPHYLAXIS; BLEEDING; CARDIOVASCULAR PROCEDURES; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FREQUENCY ANALYSIS; HEART MUSCLE NECROSIS; HUMAN; HYPERSENSITIVITY REACTION; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; PROSPECTIVE STUDY; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; PHASE 4 CLINICAL TRIAL;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE IV; CORONARY DISEASE; HUMAN; IMMUNOGLOBULINS, FAB; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOCYTOPENIA; TREATMENT OUTCOME; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS;

EID: 0035997865     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Glycoprotein inhibitors and fibrinolysis in myocardial infarction
2. Safe use of platelet GP IIb/IIIa inhibitors
3. Abciximab readministration: Results of the ReoPro Readministration Registry
4. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy
5. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia
6. Heparin-associated thrombocytopenia
7. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia
8. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions
9. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation
10. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG investigators
11. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
12. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade. The EPISTENT investigators. Evaluation of platelet for stenting
13. Troponisms, necrosettes, enzyme leaks, creatinine phosphokinase bumps, and infarctlets: What's behind this new lexicon and what does it add?
14. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment
15. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization